FGF19 and hepatocellular carcinoma: H3B-6527 also targets Cysteine 552 through forming a covalent bond near the ATP binding site of FGFR4, and it exhibits an inhibitory effect on FGFR4 activation in FGF19-driven HCC in vitro and in vivo [64].